Adicet Bio, Inc. Common Stock
$9.18
Market Cap
$85.94M
Shares Outstanding
9.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 16, 2020
Round Lot
100
Locale
US
Day Open
$8.96
Day High
$9.40
Day Low
$8.76
Volume
114.5K
VWAP
$9.16
Prev Close
$9.01
Transactions
--
Acc. Volume
--
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Adicet Bio, Inc. Common Stock (ACET) closed the 2026-09-18 session at $9.18, up 1.89% versus the previous close (+0.17). The stock opened at $8.96 and traded between $8.76 and $9.40 during that session. Session trading volume was 115K shares. The volume-weighted average price (VWAP) is $9.16.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Adicet Bio, Inc. Common Stock has a market capitalization of $85.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ACET is listed on the XNAS exchange. The company employs approximately 102 people. Adicet Bio, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2020-09-16.
On this page you can find market ACET stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.